This Week in Managed Care—Step Therapy in Medicare Advantage and Other Health News

Managed Care Cast

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast. This week, the top managed care stories included, CMS allowing step therapy in Medicare Advantage plans in a bid to allow for drug price negotiation; larger practices with more resources, technology and care management processes have higher readmission rates than smaller practices; studies find that empagliflozin also reduces liver fat in patients with diabetes and nonalcoholic fatty liver disease. Read more about the stories in this podcast: CMS Will Allow Medicare Advantage Plans to Use Step Therapy to Negotiate Drug Prices: https://www.ajmc.com/newsroom/cms-will-allow-medicare-advantage-plans-to-use-step-therapy-to-negotiate-drug-prices CMS Approves Extra Payments for CAR T, Increases Other Payments in Final Rule: https://www.ajmc.com/newsroom/cms-approves-extra-payments-for-car-t-increases-other-payments-in-final-rule Larger Practices Spend More on, Have Higher Readmission Rates for Medicare Beneficiaries: https://www.ajmc.com/focus-of-the-week/larger-practices-spend-more-on-have-higher-readmission-rates-for-medicare-beneficiaries Liquid Biopsy Identifies Patients More Likely to Benefit From Immunotherapy in NSCLC: https://www.ajmc.com/newsroom/liquid-biopsy-identifies-patients-more-likely-to-benefit-from-immunotherapy-in-nsclc Studies Point to Empagliflozin as First Choice for Fatty Liver Disease in T2D: https://www.ajmc.com/newsroom/studies-point-to-empagliflozin-as-first-choice-for-fatty-liver-disease-in-t2d Discussing Increased Prevalence of NAFLD and NASH, and the Current Lack of Treatments: https://www.ajmc.com/managed-care-cast/discussing-increased-prevalence-of-nafld-and-nash-and-the-current-lack-of-treatments